Alessandro Lagana' | Ricerc@Sapienza

Publications

Title	Published on	Year
Red Blood Cell Distribution Width May Predict Drug-Induced Anemia and Prognosis in Patients Affected by Primary/Secondary Myelofibrosis Treated with Ruxolitinib	ONCOLOGY AND THERAPY	2025
Neutrophil to lymphocyte ratio in myelofibrosis patients treated with ruxolitinib may predict prognosis and rate of discontinuation	EUROPEAN JOURNAL OF HAEMATOLOGY	2024
Evaluation of VTE-PREDICT Risk Score in Patients Receiving Low-Dose DOACs for Venous Thromboembolism (VTE) Secondary Prophylaxis	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Secondary Prophylaxis of Venous Thromboembolism (VTE) with Low Dose Apixaban or Rivaroxaban: Results from a Patient Population with More than 2 Years of Median Follow-up	MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES	2024
Treatment free remission (TFR) after second-generation tyrosine kinase inhibitors (2G-TKIs) treatment in chronic myeloid leukemia (CML): from feasibility to safety	EXPERT OPINION ON DRUG SAFETY	2024
Venous thromboembolism secondary prophylaxis in elderly people (over 75-year-old) with low-dose direct oral anticoagulants: single-center Italian experience	BLOOD COAGULATION & FIBRINOLYSIS	2024
Asciminib as a third line option in chronic myeloid leukemia	INTERNATIONAL JOURNAL OF HEMATOLOGY	2023
One-month qRT-PCR BCR::ABL1 transcript threshold to predict early recurrence in chronic phase CML patients attempting first treatment free remission	EUROPEAN JOURNAL OF HAEMATOLOGY	2023
Reduced Klebsiella pneumoniae carbapenemase-producing K. pneumoniae (KPC-KP) colonization in a hematological-emergency setting during the coronavirus disease 2019 (COVID-19) pandemic	INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY	2022
Novel therapeutic agents for myelofibrosis after failure or suboptimal response to JAK2 inhbitors	CURRENT OPINION IN ONCOLOGY	2022